Dosage Adjustments for Chemotherapy and Targeted Therapies in Colorectal and Pancreatic Cancer Patients with Hepatic Impairment

被引：4

作者：

Khalid, Sidra ^{[1
]}

Khalid, Aariez ^{[2
]}

Clark, Bernadette A. ^{[3
]}

Haddad, Abdo ^{[4
]}

Spiro, Timothy Pp. ^{[4
]}

Daw, Hamed ^{[4
]}

机构：

[1] Cleveland Clin, Fairview Hosp, Cleveland, OH 44106 USA

[2] Univ Guelph, Sci Biomed Sci, Binbrook, ON, Canada

[3] Cleveland Clin, Fairview Hosp, Oncol, Cleveland, OH 44106 USA

[4] Cleveland Clin, Fairview Hosp, Dept Hematol & Oncol, Cleveland, OH 44106 USA

来源：

CUREUS | 2018年 / 10卷 / 06期

关键词：

hepatic impairment; colon cancer; rectal cancer; pancreatic cancer; chemotherapy; targeted therapy;

D O I：

10.7759/cureus.2798

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There are many novel chemotherapeutic options and targeted therapies available for the treatment of colorectal and pancreatic cancer. Patients with these cancers often have hepatic impairment either from the metastasis to the liver or from the chemotherapy or targeted therapies used to treat the disease. It is important to describe the effects of these agents in patients with hepatic impairment. This article will review the dosage recommendations for the chemotherapy regimens and targeted therapies in colorectal and pancreatic cancer patients in the setting of hepatic impairment.

引用

页数：9

共 32 条

[1]

[Anonymous], 2018, SUNITINIB EVEROLIMUS

[2]

[Anonymous], 2016, ERLOTINIB DOSAGE

[3]

[Anonymous], 2013, REGORAFENIB STIVARGA

[4]

[Anonymous], 2017, IRINOTECAN HYDROCHLO

[5]

[Anonymous], 2018, IRINOTECAN

[6]

[Anonymous], 2015, XELODA CAPECITABINE

[7] Pharmacokinetics of sunitinib malate in subjects with hepatic impairment [J].

Bello, Carlo L. ;

Garrett, May ;

Sherman, Laurie ;

Smeraglia, John ;

Ryan, Bob ;

Toh, Melvin .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (04) :699-707

[8]

Cancer care Ontario, 2018, GEMC

[9]

Cancer care Ontario, 2017, FLUOR

[10] Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J].

Demetri, George D. ;

Reichardt, Peter ;

Kang, Yoon-Koo ;

Blay, Jean-Yves ;

Rutkowski, Piotr ;

Gelderblom, Hans ;

Hohenberger, Peter ;

Leahy, Michael ;

von Mehren, Margaret ;

Joensuu, Heikki ;

Badalamenti, Giuseppe ;

Blackstein, Martin ;

Le Cesne, Axel ;

Schoffski, Patrick ;

Maki, Robert G. ;

Bauer, Sebastian ;

Binh Bui Nguyen ;

Xu, Jianming ;

Nishida, Toshirou ;

Chung, John ;

Kappeler, Christian ;

Kuss, Iris ;

Laurent, Dirk ;

Casali, Paolo G. .

LANCET, 2013, 381 (9863) :295-302

← 1 2 3 4 →